A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

This study is testing whether giving two immunotherapy drugs — cemiplimab and fianlimab — before surgery can help shrink kidney cancer tumors and improve outcomes for people with high-risk, non-metastatic clear cell renal cell carcinoma who are planned for surgical removal of the kidney. **You may be eligible if...** - You are 18 years or older - You are planned to have your kidney removed (nephrectomy) for high-risk, non-metastatic clear cell renal cell carcinoma - Your cancer has not spread to distant organs (regional lymph node involvement is acceptable) **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have previously received immunotherapy or targeted therapy for kidney cancer - You have active autoimmune disease - You have significant organ dysfunction Talk to your doctor to see if this trial is right for you.